Savara Inc. Common Stock (SVRA)

About SVRA

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

70

Website

savarapharma.com/

Fundamentals

1-day range

$5.25$5.51

Market cap

$1.09B

P/E (trailing)

—

P/E (forward)

-16.86

EPS (trailing)

$-0.56

Dividend yield

—

Beta

0.18

Avg. volume

1.82M

Dividend pay date

April 28, 2017

Forecasts

8 analyst ratings

Savara Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SVRA

  Savara Inc. Common Stock

  $5.27

  ▼ 4.10%
  Market cap $1.09BP/E —
  $3.19$7.01
• CRVS

  Corvus Pharmaceuticals Inc. Common Stock

  $14.15

  ▼ 3.87%
  Market cap $1.12BP/E —
  $5.28$26.95
• SDGR

  Schrodinger Inc. Common Stock

  $19.7

  ▼ 3.48%
  Market cap $1.14BP/E —
  $10.95$23.02
• LXRX

  Lexicon Pharmaceuticals Inc. Common Stock

  $2.29

  ▼ 1.29%
  Market cap $1.03BP/E —
  $1.03$2.68
• IVA

  Inventiva S.A. American Depository Shares

  $4.71

  ▼ 3.98%
  Market cap $1.00BP/E —
  $2.88$6.2
• OLMA

  Olema Pharmaceuticals Inc. Common Stock

  $10.28

  ▼ 4.77%
  Market cap $985.28MP/E —
  $5.36$36.26
• MNKD

  MannKind Corporation Common Stock

  $3.96

  ▼ 2.59%
  Market cap $1.21BP/E —
  $2.23$6.51

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress
  benzinga · 8/24/2026
• Top movers in Tuesday's after hours session
  ChartMill · 8/18/2026
• Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
  Yahoo · 8/11/2026
• Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041
  Benzinga · 8/11/2026
• Savara Q2 EPS $(0.16) Misses $(0.14) Estimate
  Benzinga · 8/11/2026
• What Insmed Stock's Premium Is Actually Buying
  Yahoo · 8/7/2026
• Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
  SeekingAlpha · 8/5/2026

• Robert Matthew Lutz · July 15, 2026 · Grant

  70.0K
• Robert Matthew Lutz · July 15, 2026 · Grant

  35.0K
• David L. Lowrance · June 22, 2026 · Option Exercise

  87.7K @ $3.35
• David L. Lowrance · June 22, 2026 · Option Exercise

  12.5K @ $4.45
• David L. Lowrance · June 22, 2026 · Option Exercise

  218.8K @ $1.51
• David L. Lowrance · June 22, 2026 · Option Exercise

  56.9K @ $1.11
• David L. Lowrance · June 22, 2026 · Option Exercise

  129.3K @ $1.23
• David L. Lowrance · June 22, 2026 · Option Exercise

  75.0K @ $1.59
• David L. Lowrance · June 22, 2026 · Sale

  394.5K @ $5.68
• David L. Lowrance · June 22, 2026 · Tax Withholding

  53.4K @ $5.5
• David L. Lowrance · June 22, 2026 · Tax Withholding

  10.1K @ $5.5
• David L. Lowrance · June 22, 2026 · Tax Withholding

  60.1K @ $5.5
• David L. Lowrance · June 22, 2026 · Tax Withholding

  11.5K @ $5.5
• David L. Lowrance · June 22, 2026 · Tax Withholding

  28.9K @ $5.5
• David L. Lowrance · June 22, 2026 · Tax Withholding

  21.7K @ $5.5

Institutional Ownership

March 31, 2026

Total shares held

209.77M

Total value held

$1.14B

Institutional holders

179